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INTRODUCTION G protein coupled receptor (GPCR) internalization as a means of receptor regulation has been associated with conditions as wide-ranging as opioid analgesia to opioid addiction (Alverez et al., 2001; Connor et al., 2004; Gainetdinov et al., 2004; Bohn et al., 2004a; . Agonist-induced, GPCR kinase (GRK)-mediated phosphorylation, subsequent β-arrestin protein binding, the assembly of clathrin coated vesicles and vesicular internalization describe a general paradigm for GPCR internalization (Shenoy and Lefkowitz 2003; Pierce and Lefkowitz 2001) . The µ opioid receptor (µOR), however, has been shown to be differentially regulated depending on agonist occupancy. For example, while both morphine and etorphine are agonists at the µOR and can promote receptor desensitization and analgesic tolerance, morphine appears to be much less effective in promoting receptor phosphorylation, β-arrestin recruitment, and µOR internalization than etorphine (Zhang et al., 1998; Whistler and von Zastrow, 1998; Bohn et al., 2004b) . Interestingly, each of these limitations can be overcome by overexpression of GRK2 in cell culture suggesting that the agonist occupancy promotes different receptor conformations that can determine overall receptor regulation in a GRKdependent manner (Zhang et al., 1998; Bohn et al., 2004b) .
The β-arrestin proteins, namely β-arrestin-1 (βarr1) and β-arrestin-2 (βarr2), play an important role in GPCR trafficking (Pierce and Lefkowitz 2001) . While the morphinebound µOR appears to be a poor substrate for βarr2 binding, a combination of both animal and cellular studies suggest that βarr2 is prominently involved in µOR regulation.
Mice that lack βarr2 display enhanced and prolonged morphine analgesia with limited This article has not been copyedited and formatted. The final version may differ from this version. 
5 development of tolerance (Bohn et al., 1999; 2000a; Przewlocka et al. 2002) .
Somewhat surprisingly, these animals are not as susceptible to the morphine-induced side effects including constipation and respiratory suppression .
Therefore the µOR-βarr2 interactions may represent a point at which agonist-directed signaling events diverge Bruns et al., 2006) .
Opioid agonists that do not induce receptor-βarr2 interactions or the subsequent receptor internalization may be promising candidates for dissociating the therapeutic effects from the unwanted side effects that usually confound opiate therapy. Recently, salvinorin A, a diterpene isolated from Salvia divinorum, was classified as a potent opioid receptor agonist (Ortega et al., 1992; Roth et al., 2002 ) that produces less receptor trafficking (Wang et al, 2005) . Salvinorin A is selective for kappa opioid receptors (κOR) and acts as a potent and efficacious agonist in G protein coupling and adenylyl cyclase assays; however, it promotes 40-fold less efficient κOR internalization than what is seen by the typical kappa agonists including U50,488H (Roth et al., 2002; Chavkin et al., 2004; Wang et al, 2005) . The chemical structure of the compound is unique in that it lacks a basic nitrogen atom, a property that is conserved among all other known opioid receptor agonists and thought to play a critical role in ligand binding. Together, these findings suggest that the κOR conformation induced by salvinorin A binding is conducive to G protein mediated signal transduction but resistant to internalization-mediated regulation.
Chemical derivatives of salvinorin A were recently described and here we report on one such derivative that has greater affinity for the µOR over the κOR (µ/κ = 0.13 from This article has not been copyedited and formatted. The final version may differ from this version. 
6 Harding et al., 2005) . This unique compound, termed, herkinorin ((2S,4aR,6aR,7R,9S,10aS ,10bR)-9-(Benzoyloxy)-2-(3-furanyl)dodecahydro-6a,10b-dimethyl-4,10-dioxo-2H-naphtho-[2,1-c]pyran-7-carboxylic acid methyl ester, (Harding et al., 2005) ) activates the µOR, leads to very little receptor phosphorylation, does not recruit βarr2 and does not lead to receptor internalization, even in the presence of overexpressed GRK2. Therefore, compounds based upon this structure may provide insight into the mechanisms of ligand-directed µOR regulation and may represent a step in the development of opiate analgesics that promote pain relief with limited adverse effects.
MATERIALS & METHODS:
Drugs: DAMGO (Tocris, Ellisville, MO), morphine sulfate, and naloxone (Sigma, St.
Louis, MO) were prepared as 10mM stocks in phosphate buffered saline. Herkinorin (referred to as "analog 13" in Harding et al., 2005) was prepared in DMSO as a 10 mM stock. Dilutions were made directly into minimal essential media (without phenol red for confocal imaging). Herkinorin is subject to degradation; therefore, drugs were produced in small batches, protected from light and not stored in DMSO or extensively as a powder.
Phospho-ERK1/2 immunoblot assay: HEK-293 cells stably expressing an haemagglutinin (HA-N-terminus) tagged mouse µOR (~2 pmol/mg membrane protein)
were assessed for agonist-induced ERK1/2 phosphorylation. Cells were serum starved at 37°C under 5% CO 2 for 30 min prior to drug treatment. Cells were stimulated for the This article has not been copyedited and formatted. The final version may differ from this version. 
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7 times indicated and cell lysates were prepared on ice in lysing buffer (20 mM Tris HCl pH 7.5, 150 mM NaCl, 2 mM EDTA, 0.1% SDS, 1% NP40, 0.25% deoxycholate, 1 mM sodium orthovanadate, 1 mM PMSF, 1 mM NaF, with Complete Mini, EDTA-free protease inhibitor cocktail tablet (Roche Diagnostics, Indianapolis, IN)). Protein levels were determined by the BioRad DC protein assay system (BioRad, Hercules, CA) and 20 µg protein per lane were resolved by 1-D gel electrophoresis on 10% Bis-Tris gels (BioRad or Invitrogen, Carlsbad, CA). Proteins were transferred to polyvinylidene fluoride (PVDF) membranes (Immobilon P, Millipore, Billerica, MA) and immunoblotted for phosphorylated ERK1/2 (p-ERK E-4: sc-7383, Santa Cruz Biotechnology, Inc., Santa Cruz, CA). Blots were stripped and blotted for total ERK1/2 levels (p44/42 MAP kinase Antibody, Cell Signaling Technology, Danvers, MA) which were used to normalize the overall phosphorylation of ERK1/2 between samples (Bohn et al., 2000b) . Chemiluminescence was detected and quantified using the Kodak 2000R imaging system (Eastman Kodak Company, Rochester, NY) and GraphPad Prism software (GraphPad Software, Inc., San Diego, CA). Mouse embryonic fibroblasts expressing (MEF-WT) and lacking endogenous βarrestins 1 and 2 (MEF βarr1&2-KO) were kindly provided by Dr. Robert Lefkowitz (Kohout et al., 2001; Bohn et al., 2004b) .
The µOR expression in MEFs was obtained by using retroviral expression vectors. ERK activation studies were performed in parallel to trafficking studies to assure activity of the agonists. 
Phosphorylated µOR
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9 to saline-treated controls in each blot. Data were analyzed using GraphPad Prism software (GraphPad Software, Inc., San Diego, CA).
Cross-linking and Co-Immunoprecipitation. HEK-293 stably expressing the µOR tagged at the N-terminal with HA were used and the procedure is based on those described by Shenoy et al., (2006) Following 3 washes in phosphate buffered saline, immunofluorescence was assessed using a Fusion Plate Reader (Perkin Elmer, Boston, MA). Data are normalized to the controls in which no agonists were added. Non-specific secondary antibody interactions were subtracted from each point. Images were taken following the experiment using a 10X objective to assure that cells had remained uniformly attached; images were also taken of these cells. If cells came off the plate, the measurements were deleted for that well. Cells were also treated in parallel to this experiment in small confocal dishes.
After 60 minutes of treatment, cells were processed in the same manner as above and immunofluorescent images were taken using a 40X objective via confocal microscopy.
Biotinylated Receptor Internalization. HEK-293 stably expressing the µOR tagged at the N-terminal with HA were used for cell surface biotinylation experiments based methods previously described (Cao et al., 1998) . Cells were washed once with cold phosphate buffered saline (PBS) then sulfo-NHS-SS-biotin (Pierce, 600 µg/mL in PBS) was added to each dish and cells were incubated for 30 minutes at 4°C. Cells generally came off of the plates and were therefore collected, combined and spun down at 2,000 rpm for all subsequent washes. Cells were washed in Tris-buffered saline (TBS, 50 mM Tris-HCl 7.4pH, 150 mM NaCl) to quench unreacted biotin. Cells were divided into This article has not been copyedited and formatted. The final version may differ from this version. Glutathione is quenched with 15 minute incubation on ice in iodacetamide buffer (50 mM iodacetamide, 1% BSA in PBS (pH 7.4)). Cells were resuspended in Triton X-100 extraction buffer (TXB: 10mM Tris (pH7.5), 120 mM NaCl , 25 mM KCl, 1mM PMSF, 1 protease inhibitor pellet/ 10 mL (Roche, ), 1 mg/mL iodoacetamide, 0.5% Triton X-100) and solubulized on ice for 2 hours. Lysates were cleared by 12,000 rpm spin and then added to avidin-conjugated agarose beads (Pierce) for immunoprecipitation overnight at 4°C with rotation. Immunoprecipitates were centrifuged at 12,000 rpm and washed 3 times with TXB and once with PBS + 0.1% SDS. Immunoprecipitates were washed and proteins were eluted and resolved as described in the co-immunoprecipitation experiments. Immunoblots were performed using the µOR C-terminal directed antibody (Neuromics), donkey anti-rabbit secondary antibody and enhanced chemiluminescence detection as described above. Several controls were performed and they are as follows:
1) "100%" refers to total surface receptors and represents cells lysed directly following biotinylation and washes. 2) "Strip" refers to cells that have been biotinylated and then stripped; this serves as a control for the effectiveness of the glutathione stripping buffer.
3) Mock: Same as 100% but in cells that are stably mock transfected with empty vector (no µOR). 4) No protein refers to immunoprecipitation in the absence of cellular lysate.
This article has not been copyedited and formatted. The final version may differ from this version. 13 Statistics: Statistical analyses were performed using the GraphPad Prism software (GraphPad Software, Inc., San Diego, CA) and the specific tests used are presented in the figure legends.
RESULTS:
The chemical synthesis of herkinorin from salvinorin A has been previously described;
the chemical structures of herkinorin and salvinorin A are presented in Figure 1 for reference (Harding et al., 2005) . Receptor binding assays revealed that Herkinorin has a greater affinity for µOR over κOR and very little affinity for the δOR; G protein coupling assays determined that Herkinorin preferentially activates the µOR (Harding et al., 2005) .
In order to assess Herkinorin agonist activity in parallel with the current studies, we used Figure 2C (Belcheva et al., 1998) . Similar results were also obtained using
CHO cells expressing the human µOR (data not shown). A comparison of ERK
phosphorylation between DAMGO and Herkinorin reveals comparable potencies, although there is a tendency for herkinorin to continue to activate ERK past the efficacy observed with DAMGO ( Figure 2) . In order to test whether βarrestins are required to mediate µOR signaling to ERK we examined ERK1/2 phosphorylation in MEFs that lack both βarrestin1 and βarrestin2 and found that ERK1/2 could be activated in the absence of βarrestins ( Figure 2D ) (Kohout et al., 2001; Bohn et al., 2004a) .
This article has not been copyedited and formatted. The final version may differ from this version. Since agonist activation of many GPCRs leads to GRK-mediated receptor phosphorylation, β-arrestin recruitment and internalization, we compared herkinorin to other opiate agonists for their ability to regulate the µOR in HEK-293 cells, a model system routinely used to study opioid receptor regulation and trafficking. While both morphine and DAMGO activate the µOR, morphine is much less effective in promoting receptor phosphorylation (Figure 3 ) which is thought to underlie the decreased receptor trafficking that results from morphine binding (Whistler and von Zastrow 1998; Zhang et al., 1998; Bailey et al., 2003 , Bohn et al., 2004b Schulz et al., 2004; Koch et al 2005) .
Herkinorin resembles morphine in that it does not promote robust phosphorylation of the µOR at serine 375 (Figure 3 ).
Agonist-induced βarr2 translocation in response to morphine, DAMGO or herkinorin was assessed by confocal imaging of live cells. HEK-293 cells expressing both the µOR and a GFP tagged β-arrestin-2 (βarr2-GFP) were stimulated with agonist for the times indicated. Images were collected from the same plate of cells prior to and following drug treatment. Shown here are representative images at the indicated time points. The translocation of βarr2-GFP to the receptor is robust with DAMGO as compared to morphine ( Figure 4A ; Zhang et al., 1998; Bohn et al., 2004b) . Herkinorin resembles morphine in that it does not appear to induce βarr2-GFP translocation to the µOR ( Figure   4A ). Cells were also observed at earlier (real time video every 30 seconds for first 10 minutes) and later time points (15, 20, 30, 60, 120 minutes) to assess whether herkinorin could recruit endogenous βarrestins to the receptors, we stimulated the µOR expressing cells with drug, stabilized the βarrestin-receptor complex using a cross-linking reagent, immunoprecipitated the HA-tagged µOR and blotted for βarrestins using the A1CT βarrestin antibody (Shenoy et al., 2006; Gesty-Palmer et al., 2006) . While DAMGO promoted µOR-βarrestin interactions, vehicle and herkinorin did not ( Figure 4B ).
Morphine can induce βarr2-GFP translocation when GRK2 is overexpressed in HEK-293 cells (Zhang et al., 1998; Bohn et al., 2004b) . While this cellular manipulation is sufficient to promote morphine-induced translocation; the overexpression of GRK2 does not promote herkinorin-induced βarr2-GFP translocation to the µOR ( Figure 4C ). In order to be certain that the cells imaged had been transfected with GRK2, morphine was applied after herkinorin treatment and translocation was observed. Morphine does not normally induce βarr2-GFP translocation in the absence of GRK2 overexpression ( Figure   4A , therefore, a positive response to morphine was taken as evidence that the cell was overexpressing GRK2. Conversely, a combination of morphine and herkinorin was not sufficient to induce translocation in cells that did not overexpress GRK2 (data not shown).
Since βarrestin-GPCR interactions precede receptor vesicular internalization, it is not surprising that DAMGO leads to robust receptor internalization, while morphine does not Figure 5B,C). A cell surface protein biotinylation approach was also used to assess receptor internalization following drug treatment ( Figure 5D ) (Cao et al., 1998) .
DAMGO induced a significant increase in internalized receptors while vehicle and herkinorin did not.
The overexpression of GRK2 can promote morphine-induced µOR internalization as it does βarr2-GFP translocation ( Figure 4C ), suggesting that the agonist occupancy promotes a conformation that differs between DAMGO and morphine at the level of GRK-mediated phosphorylation of the agonist-bound receptor (Zhang et al., 1998; Bohn et al., 2004b) . However, overexpression of GRK2 is insufficient to promote herkinorininduced µOR internalization ( Figure 6A ) further demonstrating the differences between morphine and herkinorin with respect to agonist-induced µOR trafficking.
GPCR phosphorylation and internalization can be altered by changing the serine and threonine numbers in the C-terminal tail (Oakley et al, 2001) . A naturally occurring splice variant of the mouse µOR, µOR1-D, differs from the µOR only in the C-terminal This article has not been copyedited and formatted. The final version may differ from this version. Koch et al., 2001; Pan et al., 1999) .
The µOR1-D internalizes with morphine treatment while herkinorin fails to internalize this receptor variant ( Figure 6B ). Taken together, our findings demonstrate that unlike morphine, the herkinorin-bound µOR does not internalize or recruit βarr2-GFP in HEK-293 cells and this cannot be overcome by overexpressing GRK2 or by substituting the µOR1-D splice variant.
DISCUSSION:
Herkinorin is a µOR agonist that does not promote βarr2-GFP translocation or µOR internalization. It differs from morphine which can promote βarr2-GFP translocation and receptor internalization when GRK2 is overexpressed in the µOR-expressing HEK-293 cells. Herkinorin could be classified as a biased agonist of the µOR as it induces signaling through one pathway (MAP kinase) while it does not promote an interaction with another pathway (βarrestin translocation and receptor internalization). Agonists that can activate the receptor may be therapeutically useful considering that suppression of the βarrestin2-µOR interaction attenuates morphine antinociceptive tolerance and morphineinduced side effects in genetically modified mouse models (Bohn et al., 2000; Przewlocka et al. 2002; .
Nearly a decade ago, Burford et al. (1998) first described how morphine and DAMGO could be considered as "biased agonists" as both ligands could efficiently activate G
proteins, yet only DAMGO induced robust µOR internalization in HEK-293 cells.
This article has not been copyedited and formatted. The final version may differ from this version. Shenoy et al., 2006 ). An earlier study by Kohout et al. (2004) , describes a similar effect for CCL7 receptor activation by the two agonists-CCL19 and CCL21 wherein they show that while both agonists activate G protein mediated signaling, only CCL19 places the receptor into a conformation that can be phosphorylated and desensitized by βarrestins. Phosphorylation at the C-terminus was found to be important for the CCL19-mediated desensitization, and it was likely that both GRKs and protein kinase C (PKC) could play a role in the phosphorylation. The µOR is also phosphorylated by both GRKs and PKCs. Extensive work by the Chavkin group has indicated several potential residues by which the µOR can be phosphorylated by GRKs as well as by PKC and they have further shown that the phosphorylation profiles are tightly linked to agonist-specific regulation (Celver et al., 2001; Lowe et al., 2004; Celver et al., 2004 ). We have not evaluated the role of other protein kinases on regulation of the herkinorin-bound µOR, yet it is likely that some form of receptor regulation will occur.
Further, our studies have examined phosphorylation of only one residue implicated in desensitization and it is likely that other phosphorylation sites in the receptor can impact receptor regulation. Further studies of this compound and its derivatives are ongoing.
To test for agonist activity of the compound in parallel with the trafficking studies, we employed a MAP kinase assay and found that Herkinorin could lead to phosphorylation of ERK1/2 in a dose-dependent, antagonist reversible manner (Figure 2) . A recent report
This article has not been copyedited and formatted. The final version may differ from this version. by Wang et al. (2006) reports that βarrestins can serve as a molecular switch in the activation of ERK via SRC mediated by α2 adrenergic receptor activation. In the absence of βarrestins, they found that ERK phosphorylation persisted over time and that the phospho-ERK was predominantly localized to the nucleus at the later time points.
Herkinorin treatment activates of ERK in a manner that appears to be more efficacious than DAMGO which may be due to a more persistent signal. Whether the altered ERK activation profile is due to a similar mechanism as those described for the α2 adrenergic receptors in the absence of βarrestins remains to be determined. We have found that the µOR activates ERK in the absence of βarrestins using mouse embryonic fibroblasts that lack endogenous βarrestin1 and βarrestin2 and these cells will be useful for further elucidating the contribution of the βarrestins to the µOR activation of MAP kinase pathways. Moreover, the physiological significance of such molecular events downstream of µOR remain to be determined.
The implications of how opiates that can activate the receptor without recruiting βarrestins will act in vivo remain to be seen. In studies using mice lacking βarrestin-2, morphine produced enhanced and prolonged antinociception with very little morphine tolerance (Bohn et al., 1999 (Bohn et al., , 2000 (Bohn et al., , 2002 . Therefore, opioid agonists that do not promote receptor-βarrestin interactions may mimic the effect of blocking the βarrestins and result in analgesics that do not promote tolerance. Moreover, agonists that activate the µOR without the recruitment of βarrestins may have additional benefits besides preventing antinociceptive tolerance. Recently, morphine-induced side effects, including constipation and respiratory suppression, were shown to be greatly diminished in mice This article has not been copyedited and formatted. The final version may differ from this version. 
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20 lacking βarr2 . The mechanisms that determine how one µOR-mediated physiological response can be enhanced while another is suppressed due to the ablation of βarr2 is not known; however, these observations speak to the diverse roles that βarrestins may play in receptor signaling as well as regulation (Shenoy and Lefkowitz, 2003) . If βarr2-opioid receptor interaction is required for opioid-induced constipation and respiratory suppression, then compounds that can activate the µOR and not recruit the βarrestins may be promising opioid analgesics with much fewer side effects (Bruns et al., 2006) .
The question remains as to whether the βarrestin translocation and internalization profiles observed in the cellular system are preserved at the biological sites of action in vivo.
This is an important consideration as morphine has been shown to promote efficient internalization profiles in certain neuronal populations while promoting no internalization in other neurons (Keith et al., 1996; Haberstock-Debic et al., 2003; . Here we have used the HEK-293 cellular system to assess the herkinorin-induced µOR trafficking profiles since this model has been the most extensively used to study opioid receptor trafficking and should allow for the best overall comparison of herkinorin to other opioids. Ultimately, receptor trafficking induced by herkinorin and other opiates should be compared in neurons that mediate opiate-induced antinociceptive effects.
Salvinorin A is biologically active in vivo as it produces hallucinations by its actions at
the κOR yet these effects are very short-lasting (Roth et al., 2002) . Systemic injections of herkinorin into mice and rats do not produce analgesic responses; however, peripheral
This article has not been copyedited and formatted. The final version may differ from this version. Moreover, poor solubility of the compound makes it difficult to administer high concentrations systemically. Further modifications of the herkinorin template are being generated with hopes of identifying a compound with greater stability and solubility than herkinorin.
The structure of herkinorin, as well as salvinorin A and its related compounds, is unique Activation of µOR in the absence of βarrestins (βarr1&2-KO MEFs) still leads to ERK1/2 phosphorylation. Immunoblots were performed as described above using lysates from MEFs. Remaining surface proteins were then subjected to glutathione cleavage of biotin. Cells were then lysed and remaining biotinylated proteins were immunoprecipiated with avidin-conjugated agarose beads. Proteins were resolved via SDS-PAGE under reducing conditions. Immunoblotting was performed with the C-terminal specific µOR antibody (Neuromics, Edina, MN). 100% represents cells that were not stripped with glutathione. This article has not been copyedited and formatted. The final version may differ from this version. 
